/ITCI
ITCI Stock - Intra-Cellular Therapies, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$131.87+0.00%
+$0.00 (+0.00%) • Apr 2
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.84
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).50
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+0.1%upside
Target: $132.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ITCI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$130.55 – $133.19
TARGET (TP)$132.00
STOP LOSS$121.32
RISK/REWARD1:0.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.46
52W High$131.98
52W Low$64.09
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $680.85M | $464.37M | $249.13M | $81.71M | $22.53M |
| Gross Profit | $623.89M | $430.63M | $228.69M | $73.67M | $20.64M |
| Gross Margin | 91.6% | 92.7% | 91.8% | 90.2% | 91.6% |
| Operating Income | $-116,721,000 | $-159,381,000 | $-263,626,000 | $-285,688,125 | $-231,227,631 |
| Net Income | $-74,676,000 | $-139,674,000 | $-256,256,000 | $-284,125,666 | $-227,005,663 |
| Net Margin | -11.0% | -30.1% | -102.9% | -347.7% | -1007.5% |
| EPS | $-0.72 | $-1.46 | $-2.72 | $-3.50 | $-3.23 |
Company Overview
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
50%
Hold / Neutral
4
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
4 Bullish4 Neutral/Bearish
Price Targets
$85
Average Target
↓ 35.5% Downside
Now
$49
Low
$85
Average
$132
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 24th 2025 | Mizuho | Downgrade | Neutral | $132← $140 |
| January 31st 2025 | Canaccord Genuity | Downgrade | Hold | $132← $119 |
| September 6th 2024 | Piper Sandler | Upgrade | Overweight | $92← $68 |
| January 3rd 2024 | Robert W. Baird | Initiation | Outperform | $83 |
| December 11th 2023 | TD Cowen | Initiation | Outperform | $75 |
| April 20th 2023 | Morgan Stanley | Initiation | Overweight | $80 |
| August 22nd 2022 | Goldman | Downgrade | Neutral | $49← $64 |
| July 7th 2022 | Mizuho | Initiation | Buy | $74 |
| June 14th 2022 | UBS | Initiation | Buy | $75 |
| April 22nd 2022 | Piper Sandler | Initiation | Neutral | $59 |
Earnings History & Surprises
ITCIBeat Rate
65%
Last 20 quarters
Avg Surprise
+9.1%
EPS vs Estimate
Beats / Misses
13/6
1 met exactly
Latest EPS
$-0.16
Q1 2025
EPS Surprise History
Q2 23
+27.0%
$-0.46vs$-0.63
Q3 23
+27.4%
$-0.45vs$-0.62
Q4 23
+57.6%
$-0.25vs$-0.59
Q1 24
+31.8%
$-0.30vs$-0.44
Q2 24
+48.4%
$-0.16vs$-0.31
Q3 24
+11.1%
$-0.16vs$-0.18
Q4 24
-38.9%
$-0.25vs$-0.18
Q1 25
-100.0%
$-0.16vs$-0.08
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2025 | Feb 21, 2025 | $-0.08 | $-0.16 | -100.0% | ✗ MISS |
Q4 2024 | Oct 30, 2024 | $-0.18 | $-0.25 | -38.9% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.18 | $-0.16 | +11.1% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.31 | $-0.16 | +48.4% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.44 | $-0.30 | +31.8% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.59 | $-0.25 | +57.6% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.62 | $-0.45 | +27.4% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.63 | $-0.46 | +27.0% | ✓ BEAT |
Q1 2023 | Mar 1, 2023 | $-0.62 | $-0.45 | +27.4% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.86 | $-0.57 | +33.7% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.79 | $-0.92 | -16.5% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.93 | $-0.78 | +16.1% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-1.05 | $-1.05 | 0.0% | = MET |
Q4 2021 | Nov 9, 2021 | $-0.89 | $-0.95 | -6.7% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-0.79 | $-0.85 | -7.6% | ✗ MISS |
Q2 2021 | May 10, 2021 | $-0.81 | $-0.65 | +19.8% | ✓ BEAT |
Q1 2021 | Feb 25, 2021 | $-0.85 | $-0.76 | +10.6% | ✓ BEAT |
Q4 2020 | Nov 9, 2020 | $-0.96 | $-0.79 | +17.7% | ✓ BEAT |
Q3 2020 | Aug 10, 2020 | $-0.94 | $-0.96 | -2.1% | ✗ MISS |
Q2 2020 | May 7, 2020 | $-0.98 | $-0.73 | +25.5% | ✓ BEAT |
Frequently Asked Questions about ITCI
What is ITCI's current stock price?
Intra-Cellular Therapies, Inc. (ITCI) is currently trading at $131.87 per share. The stock has moved +0.00% today.
What is the analyst price target for ITCI?
The average analyst price target for ITCI is $132.00, based on 1 analyst.
What sector is Intra-Cellular Therapies, Inc. in?
Intra-Cellular Therapies, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is ITCI's market cap?
Intra-Cellular Therapies, Inc. has a market capitalization of $14.05 billion, making it a large-cap company.
Does ITCI pay dividends?
No, Intra-Cellular Therapies, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABMD
Abiomed, Inc.
$381.02
Mkt Cap: $17.2B
BDX
Becton, Dickinson and Company
$195.59
Mkt Cap: $56.3B
CTLT
Catalent, Inc.
$63.48
Mkt Cap: $11.5B
IMGN
ImmunoGen, Inc.
$31.23
Mkt Cap: $8.7B
KRTX
Karuna Therapeutics, Inc.
$329.83
Mkt Cap: $12.6B
OSH
Oak Street Health, Inc.
$39.00
Mkt Cap: $9.5B
RVTY
Revvity, Inc.
$96.24
Mkt Cap: $11.4B
RXDX
Prometheus Biosciences, Inc.
$199.92
Mkt Cap: $9.6B
SWAV
ShockWave Medical, Inc.
$334.75
Mkt Cap: $12.6B
WBA
Walgreens Boots Alliance, Inc.
$11.98
Mkt Cap: $10.4B
Explore stocks similar to ITCI for comparison